Ironwood Pharmaceuticals Inc (IRWD)vsViatris Inc (VTRS)
IRWD
Ironwood Pharmaceuticals Inc
$3.31
-2.65%
HEALTHCARE · Cap: $544.87M
VTRS
Viatris Inc
$15.88
-0.13%
HEALTHCARE · Cap: $19.19B
Smart Verdict
WallStSmart Research — data-driven comparison
Viatris Inc generates 3928% more annual revenue ($14.56B vs $361.51M). IRWD leads profitability with a 28.3% profit margin vs -2.0%. IRWD earns a higher WallStSmart Score of 69/100 (B-).
IRWD
Strong Buy69
out of 100
Grade: B-
VTRS
Buy50
out of 100
Grade: C-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+86.3%
Fair Value
$32.43
Current Price
$3.31
$29.12 discount
Intrinsic value data unavailable for VTRS.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Attractively priced relative to earnings
Strong operational efficiency at 68.1%
Revenue surging 158.9% year-over-year
Earnings expanding 1047.0% YoY
Conservative balance sheet, low leverage
Keeps 28 of every $100 in revenue as profit
Growing faster than its price suggests
Reasonable price relative to book value
Areas to Watch
Smaller company, higher risk/reward
ROE of -575.0% — below average capital efficiency
Distress zone — elevated risk
ROE of -2.0% — below average capital efficiency
Earnings declined 70.6%
Distress zone — elevated risk
Currently unprofitable
Comparative Analysis Report
WallStSmart ResearchBull Case : IRWD
The strongest argument for IRWD centers on P/E Ratio, Operating Margin, Revenue Growth. Profitability is solid with margins at 28.3% and operating margin at 68.1%. Revenue growth of 158.9% demonstrates continued momentum.
Bull Case : VTRS
The strongest argument for VTRS centers on PEG Ratio, Price/Book. PEG of 0.14 suggests the stock is reasonably priced for its growth.
Bear Case : IRWD
The primary concerns for IRWD are Market Cap, Return on Equity, Altman Z-Score.
Bear Case : VTRS
The primary concerns for VTRS are Return on Equity, EPS Growth, Altman Z-Score.
Key Dynamics to Monitor
IRWD profiles as a growth stock while VTRS is a turnaround play — different risk/reward profiles.
VTRS carries more volatility with a beta of 0.90 — expect wider price swings.
IRWD is growing revenue faster at 158.9% — sustainability is the question.
VTRS generates stronger free cash flow (348M), providing more financial flexibility.
Bottom Line
IRWD scores higher overall (69/100 vs 50/100), backed by strong 28.3% margins and 158.9% revenue growth. Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Ironwood Pharmaceuticals Inc
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Ironwood Pharmaceuticals, Inc., a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. The company is headquartered in Boston, Massachusetts.
Viatris Inc
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Viatris Inc. is an American global healthcare company headquartered in Canonsburg, Pennsylvania.
Visit Website →Compare with Other DRUG MANUFACTURERS - SPECIALTY & GENERIC Stocks
Want to dig deeper into these stocks?